Sean McCutcheon
Stock Analyst at Raymond James
(n/a)
# 4,568
Out of 4,884 analysts
7
Total ratings
n/a
Success rate
-56.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Reinstates: Outperform | $9 | $2.85 | +216.34% | 1 | Jul 1, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Outperform | $11 | $2.56 | +330.53% | 1 | Jul 1, 2025 | |
| ENGN enGene Holdings | Initiates: Outperform | $23 | $3.79 | +506.86% | 1 | Nov 27, 2024 | |
| XNCR Xencor | Maintains: Strong Buy | $58 → $40 | $8.38 | +377.33% | 1 | Jun 14, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $92 → $70 | $34.58 | +102.43% | 2 | May 23, 2024 | |
| LEGN Legend Biotech | Initiates: Outperform | $86 | $35.50 | +142.25% | 1 | Mar 13, 2024 |
Compass Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $9
Current: $2.85
Upside: +216.34%
Black Diamond Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $11
Current: $2.56
Upside: +330.53%
enGene Holdings
Nov 27, 2024
Initiates: Outperform
Price Target: $23
Current: $3.79
Upside: +506.86%
Xencor
Jun 14, 2024
Maintains: Strong Buy
Price Target: $58 → $40
Current: $8.38
Upside: +377.33%
Cytokinetics
May 23, 2024
Maintains: Outperform
Price Target: $92 → $70
Current: $34.58
Upside: +102.43%
Legend Biotech
Mar 13, 2024
Initiates: Outperform
Price Target: $86
Current: $35.50
Upside: +142.25%